Skip to main content

Table 1 Baseline patient characteristics (safety analysis set; N = 122)

From: Using the Goal Attainment Scale adapted for depression to better understand treatment outcomes in patients with major depressive disorder switching to vortioxetine: a phase 4, single-arm, open-label, multicenter study

Sex, n (%)

 Male

21 (17.2)

 Female

101 (82.8)

Age, mean years (SD)

45.3 (12.2)

≤55 years, n (%)

95 (77.9)

Race, n (%)

 White

83 (69.2)

 Black or African American

28 (23.3)

 Asian

5 (4.2)

 Native Hawaiian or Other Pacific Islander

1 (0.8)

 Multiraciala

3 (2.5)

 Unknown

2 (1.6)

Ethnicity, n (%)

 Hispanic or Latino

28 (23.0)

Employment status, n (%)b

 Employed full-time

32 (27.6)

 Employed part-time

22 (19.0)

 Self-employed

15 (12.9)

 Not employedc

48 (41.7)

BMI, mean kg/m2 (SD)

34.1 (9.7)

PHQ-9,d mean (SD)

15.7 (4.8)

Previous antidepressant medication, n of medications (%)

 

SSRIs

  Fluoxetine

34 (16.8)

  Sertraline

25 (12.4)

  Escitalopram

24 (11.9)

  Citalopram

25 (12.4)

  Paroxetine

11 (5.4)

SNRIs

  Venlafaxine

21 (10.4)

  Duloxetine

9 (4.5)

  Desvenlafaxine

3 (1.5)

NDRIs

  Bupropion

32 (15.8)

Other

  Trazodone

9 (4.5)

  Vilazodone

6 (3.0)

  Amitriptyline

1 (0.5)

  Doxepin

1 (0.5)

  Mirtazapine

1 (0.5)

Reason for switching from previous medication, n (%)

 Inadequate response

39 (32)

 Not working fast enough

37 (30)

 Not meeting treatment goals

28 (23)

 Problems with focus/concentration

9 (7)

 Side effect

5 (4)

 Other

5 (4)

Patients with concurrent medical conditions, n (%)

122 (100)

 Blood and lymphatic system disorders

4 (3.3)

 Cardiac disorders

1 (0.8)

 Congenital, familial, and genetic disorders

2 (1.6)

 Ear and labyrinth disorders

3 (2.5)

 Endocrine disorders

20 (16.4)

 Eye disorders

17 (13.9)

 Gastrointestinal disorders

29 (23.8)

 General disorders

4 (3.3)

 Hepatobiliary disorders

2 (1.6)

 Immune system disorders

41 (33.6)

 Infections and infestations

13 (10.7)

 Investigations

17 (13.9)

 Metabolism and nutrition disorders

46 (37.7)

 Musculoskeletal and connective tissue disorders

41 (33.6)

 Neoplasms benign, malignant, and unspecified (including cysts and polyps)

1 (0.8)

 Nervous system disorders

44 (36.1)

 Renal and urinary disorders

6 (4.9)

 Reproductive system and breast disorders

10 (8.2)

 Respiratory, thoracic, and mediastinal disorders

26 (21.3)

 Skin and subcutaneous tissue disorders

17 (13.9)

 Social circumstances

23 (18.9)

 Surgical and medical procedures

4 (3.3)

 Vascular disorders

27 (22.1)

Patients with concurrent psychiatric disorders,e n (%)

 Insomnia related to another medical condition

28 (23.0)

 Anxiety

18 (14.8)

 Depression

17 (13.9)

 Generalized anxiety disorder

5 (4.1)

 Insomnia

5 (4.1)

 Attention deficit/hyperactivity disorder

2 (1.6)

 Initial insomnia

1 (0.8)

 Nightmare

1 (0.8)

 Obsessive compulsive disorder

1 (0.8)

 Panic disorder

1 (0.8)

 Performance fear

1 (0.8)

 Post-traumatic stress disorder

1 (0.8)

 Sleep disorder

1 (0.8)

 Stress

1 (0.8)

  1. Seventeen (13.8%) patients withdrew from the study: 10 voluntarily withdrew, 4 were lost to follow-up, and 3 discontinued following an adverse event
  2. aPatient checked more than one race option on the case report form. bn = 115. In cases of multiple employment statuses per patient, the patient is counted as many times as the number of employment statuses. Percentages are based on the number of patients in the full analysis set. Data for 1 patient were missing. cIncludes unemployed, student, retired, nonworking spouse, and other. dn = 110. ePsychiatric disorders excluding major depressive disorder
  3. BMI body mass index, NDRI norepinephrine-dopamine reuptake inhibitor, PHQ-9 Patient Health Questionnaire-Depressive Symptoms, SD standard deviation, SNRI serotonin and norepinephrine reuptake inhibitor, SSRI selective serotonin reuptake inhibitor